Lataa...

A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non‐small‐cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor

Uncommon mutations account for 10–15% of epidermal growth factor receptor (EGFR) mutations in patients with non‐small‐cell lung cancer. Afatinib is currently the most efficient EGFR‐tyrosine kinase inhibitor (TKI) against uncommon EGFR mutations. Here we report a 56‐year‐old woman presenting with pe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Respirol Case Rep
Päätekijät: Chen, Lun‐Che, Shih, Jin‐Yuan, Yu, Chong‐Jen, Yang, Ching‐Yao
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2019
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6456914/
https://ncbi.nlm.nih.gov/pubmed/31007929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.425
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!